powassan
viru
powv
emerg
tickborn
arboviru
present
public
health
threat
north
america
powv
lineag
ii
also
known
deer
tick
viru
strain
viru
frequent
found
ixod
scapulari
tick
implic
case
powv
enceph
unit
state
current
commerci
test
avail
detect
powv
exposur
tickborn
diseas
tbd
patient
describ
develop
analyt
valid
serolog
test
panel
detect
powv
infect
panel
use
indirect
enzym
immunoassay
eia
screen
eiaposit
sampl
reflex
laboratorydevelop
powvspecif
immunofluoresc
assay
ifa
analyt
sensit
test
panel
limit
detect
plaqu
reduct
neutral
test
prnt
titer
analyt
specif
igm
assay
igg
assay
heterologousflavivirusposit
sampl
test
sampl
collect
region
lyme
diseas
endem
seropreval
powv
tbd
sampl
versu
test
nontbd
sampl
p
evid
powv
infect
seen
sampl
collect
region
lyme
diseas
endem
test
panel
provid
sensit
specif
platform
detect
serolog
respons
powv
earli
cours
infect
neutral
antibodi
may
detect
combin
clinic
histori
panel
effect
tool
identifi
acut
powv
infect
full
spectrum
clinic
symptom
associ
infect
ixod
scapulari
tick
vector
powassan
viru
multipl
tickborn
pathogen
includ
lyme
diseas
bacterium
borrelia
burgdorferi
clinic
present
longterm
outcom
powassan
viru
infect
concurr
infect
tickborn
diseas
pathogen
remain
unknown
keyword
powassan
viru
deer
tick
viru
enzym
immunoassay
flaviviru
immunofluoresc
serolog
tickborn
diseas
tickborn
enceph
p
owassan
viru
powv
north
american
member
tickborn
enceph
complex
tbec
virus
transmit
bite
infect
tick
member
tbec
includ
follow
flavivirus
tickborn
enceph
viru
tbev
eastern
europ
western
asia
omsk
hemorrhag
fever
viru
siberia
kyasanur
forest
diseas
viru
india
alkhurma
viru
saudi
arabia
loup
ill
viru
unit
kingdom
tbec
virus
caus
wide
rang
diseas
human
mild
febril
ill
biphas
fever
enceph
hemorrhag
fever
powv
compos
two
genet
ecolog
distinct
lineag
prototyp
powv
lineag
transmit
primarili
ixod
cookei
tick
narrow
vertebr
host
rang
rare
feed
human
powassan
viru
lineag
ii
also
known
deer
tick
viru
dtv
transmit
ixod
scapulari
tick
broad
host
rang
also
transmit
infecti
agent
caus
lyme
diseas
anaplasmosi
ehrlichiosi
babesiosi
sinc
late
powv
infect
report
northeastern
midwestern
part
unit
state
well
canada
incid
increas
territori
scapulari
expand
preval
powv
tick
mammal
increas
powv
pose
increas
threat
recent
survey
scapulari
tick
collect
northwest
quadrant
wisconsin
demonstr
powv
infect
frequenc
similar
frequenc
survey
conduct
area
although
powv
rare
diagnos
caus
enceph
infect
sever
neurolog
sequela
common
addit
potenti
concurr
transmiss
tickborn
pathogen
particularli
borrelia
burgdorferi
caus
agent
lyme
diseas
previous
studi
north
america
similarli
arbovir
infect
powv
diagnosi
complex
requir
review
clinic
travel
histori
addit
knowledg
access
diagnost
test
serolog
test
remain
primari
method
diagnosi
powv
infect
emphasi
detect
powvspecif
igm
antibodi
serum
plasma
recent
commerci
laboratori
test
unavail
powv
unit
state
prior
posit
powv
igm
enzym
immunoassay
eia
result
confirm
plaqu
reduct
neutral
test
prnt
greater
increas
titer
acuteand
convalescentphas
sera
cultur
direct
identif
virusspecif
nucleic
acid
state
public
health
laboratori
center
diseas
control
prevent
cdc
mainstay
diagnost
test
describ
laboratorydevelop
serolog
test
panel
commerci
avail
refer
laboratori
detect
igg
igm
antibodi
powv
serum
plasma
sampl
first
test
panel
highli
sensit
commerci
tbec
screen
eia
per
manufactur
crossreact
flavivirus
expect
particularli
west
nile
viru
wnv
dengu
viru
denv
antibodyposit
sampl
sampl
screen
posit
confirm
powv
indirect
immunofluoresc
assay
ifa
perform
characterist
test
panel
optim
valid
studi
perform
assess
analyt
sensit
reproduc
specificitycrossreact
serolog
test
panel
use
routin
diagnost
test
assay
optim
analyt
sensit
differ
sensit
observ
viral
strain
test
lot
slide
sampl
dilut
igm
powv
igg
ifa
demonstr
optim
balanc
sensit
nonspecif
background
stain
fig
tickborn
diseas
tbd
sampl
titer
plaqu
reduct
neutral
test
use
reduct
cutoff
prnt
assay
optim
screen
dilut
confirm
one
powv
enceph
sampl
obtain
new
york
state
depart
health
nysdoh
prnt
titer
detect
tbec
eia
screen
confirmatori
powv
ifa
prnt
titer
determin
limit
detect
lod
serolog
test
panel
confirm
use
known
prnt
posit
sampl
tabl
screen
dilut
serolog
panel
show
analyt
sensit
tabl
reproduc
studi
show
accord
k
analyt
specif
due
limit
sampl
volum
avail
heterologousflaviviru
hf
sampl
set
yellow
fever
viru
yfv
vaccine
sampl
could
analyz
replic
run
two
differ
dilut
check
ifa
specif
sampl
known
posit
yfv
igg
antibodi
vaccine
posit
powv
igg
ifa
result
dilut
neg
dilut
sampl
known
posit
yfv
igm
antibodi
vaccine
posit
powv
igm
ifa
result
dilut
neg
dilut
fig
sampl
neg
test
optim
screen
dilut
use
panel
one
recent
yfv
vaccin
sampl
demonstr
crossreact
powv
igg
ifa
tabl
assay
optim
screen
dilut
hf
sampl
demonstr
signific
crossreact
tbec
igg
eia
dilut
powv
igg
ifa
specif
nontbec
hf
sampl
tabl
compar
commerci
ifa
fewer
hf
sampl
demonstr
crossreact
tbec
igm
eia
tbec
igg
eia
crossreact
seen
powv
igm
ifa
hf
sampl
run
screen
dilut
tabl
clinic
test
twentytwo
tbd
sampl
tbec
optic
densiti
od
ratio
baselin
test
powv
confirmatori
ifa
onehalf
sampl
n
tabl
ifa
posit
antibodi
powv
two
three
powv
igg
ifaposit
sampl
prnt
posit
sampl
third
sampl
sampl
neg
prnt
west
nile
viru
wnv
igg
posit
demonstr
evid
crossreact
powv
igg
ifa
eight
sampl
posit
powv
igm
ifa
neg
prnt
powv
nucleic
acid
detect
revers
transcriptionpcr
rtpcr
one
sampl
sampl
tabl
powv
seropreval
tbd
sampl
set
determin
nontbd
sampl
area
lyme
diseas
endem
n
tbec
eia
od
ratio
higher
baselin
test
powv
ifa
six
eiaposit
sampl
ifa
posit
antibodi
powv
tabl
four
sampl
igg
ifa
posit
two
sampl
ifa
posit
igg
igm
three
four
igg
ifaposit
sampl
posit
wnv
igg
demonstr
crossreact
igg
wnv
fourth
sampl
neg
prnt
powv
seropreval
nontbd
sampl
set
determin
patient
suspect
tbd
test
lyme
diseas
significantli
p
like
evid
powv
infect
asymptomat
patient
area
lyme
diseas
endem
histori
recent
tick
exposur
six
control
sampl
area
lyme
diseas
endem
tbec
eia
od
ratio
cutoff
igm
assay
none
posit
powv
ifa
none
sampl
cutoff
tbec
igg
eia
studi
confirm
serolog
crossreact
among
flavivirus
signific
frequent
observ
igg
antibodi
detect
assay
commerci
eia
igg
ifa
demonstr
poor
specif
overal
ifa
slightli
better
eia
overal
specif
flaviviru
igg
eia
report
improv
slightli
igg
ifa
addit
powv
igg
ifa
tbec
eia
screen
elimin
crossreact
seen
eia
alon
immunolog
matur
igg
antibodi
respons
tend
foster
format
antibodi
direct
epitop
greater
likelihood
crossreact
specif
flaviviru
prnt
detect
neutral
igg
antibodi
high
often
come
cost
assay
sensit
prnt
tend
sensit
detect
earli
antibodi
respons
given
less
stringent
endpoint
reduct
plaqu
versu
highli
specif
plaqu
reduct
describ
also
low
correl
prnt
ifa
titer
surpris
sinc
ifa
detect
antibodi
varieti
structur
nonstructur
viral
protein
wherea
prnt
primarili
detect
neutral
antibodi
direct
envelop
e
protein
viru
test
nontickborn
flaviviru
sampl
powv
igg
ifa
describ
demonstr
analyt
specif
compar
commerci
flaviviru
igg
ifa
overal
crossreact
associ
detect
flaviviru
igm
antibodi
significantli
lower
seen
igg
antibodi
igm
ifa
specif
higher
igm
eia
patient
suspect
flaviviru
infect
screen
sever
differ
virus
addit
powv
igm
ifa
tbec
eia
screen
elimin
crossreact
seen
igm
eia
alon
mani
commerci
avail
flaviviru
igmspecif
serolog
test
report
sensit
lower
seen
igg
assay
due
primarili
fact
prnt
consid
gold
standard
differenti
serodiagnosi
publish
report
confirm
patient
primari
flaviviru
infect
igm
respons
like
consist
antibodi
minim
virusneutr
capac
studi
assess
perform
commerci
avail
wnv
igm
eia
cdc
igm
protocolneg
sampl
found
posit
appar
lack
igm
specif
observ
assay
may
attribut
use
prnt
confirm
igm
posit
part
cdc
protocol
studi
convalescentphas
sampl
collect
patient
week
infect
use
prnt
may
help
confirm
accuraci
acutephas
detect
igm
studi
present
limit
design
sampl
collect
time
clinic
present
therefor
followup
convalescentphas
sampl
avail
lack
reliabl
accur
predic
assay
use
gold
standard
develop
flaviviru
igm
assay
requir
studi
accord
world
health
organ
singl
igmposit
result
arbovir
diagnosi
consid
presumpt
posit
confirm
rtpcr
viru
isol
andor
prnt
discrimin
potenti
crossreact
antibodi
current
studi
one
powv
igm
ifaposit
sampl
confirm
posit
powv
rtpcr
remain
igm
ifaposit
sampl
lack
detect
viral
genom
studi
perform
wnvposit
patient
show
viremia
detect
averag
day
igm
antibodi
becom
detect
median
day
midpoint
interv
rna
detect
overlap
day
therefor
rtpcr
function
sensit
confirmatori
assay
igmposit
sampl
across
time
point
current
state
diagnost
powv
infect
includ
initi
serolog
test
perform
use
igm
captur
enzymelink
immunosorb
assay
elisa
igg
elisa
confirmatori
test
util
prnt
greater
increas
antibodi
titer
acuteand
convalescentphas
sera
viru
isol
detect
virusspecif
rna
state
health
lab
cdc
offer
test
laborintens
natur
confirmatori
test
often
delay
report
final
result
beyond
period
clinic
util
addit
test
usual
limit
patient
present
neurolog
complic
therefor
littl
known
regard
overal
preval
clinic
symptom
associ
powv
infect
limit
data
regard
cocircul
lyme
diseas
powv
seropreval
midwest
publish
test
panel
describ
allow
simpl
effici
detect
acut
powv
infect
howev
due
crossreact
seen
flaviviru
igg
assay
imper
exposur
flavivirus
travel
vaccin
histori
consid
interpret
igg
test
result
panel
diagnost
tool
play
import
role
defin
full
spectrum
powv
diseas
optim
analyt
sensit
studi
perform
use
powv
antibodyposit
serum
sampl
confirm
prnt
use
reduct
cutoff
prnt
sampl
submit
new
york
state
depart
health
nysdoh
arboviru
laboratori
n
test
arboviru
enceph
panel
clinic
sampl
assess
seropreval
tbd
sampl
set
tickborn
diseas
sampl
set
consist
serumplasma
sampl
submit
lyme
diseas
test
patient
resid
wisconsin
area
lyme
diseas
endem
patient
consid
suspect
tbd
lyme
diseas
serolog
test
order
provid
eleven
serum
sampl
submit
copp
laboratori
routin
lyme
diseas
test
deidentifi
includ
studi
ninetyf
serumplasma
sampl
provid
marshfield
clinic
research
foundat
mcrf
residu
diagnost
sampl
submit
marshfield
clinic
lyme
diseas
test
sampl
mcrf
part
institut
review
board
irb
approv
research
protocol
ii
nontbd
sampl
set
nontbd
sampl
set
collect
area
lyme
diseas
endem
consist
serumplasma
sampl
collect
patient
without
symptom
tbd
without
histori
evid
recent
tick
exposur
fifti
heparin
wholeblood
sampl
healthi
asymptomat
adult
purchas
analyt
biolog
servic
ab
inc
wilmington
de
process
inhous
plasma
sampl
collect
local
biospecimen
bank
northeastern
region
unit
state
lyme
diseas
endem
fifti
plasma
sampl
collect
marshfield
clinic
residu
diagnost
sampl
submit
routin
cholesterol
complet
metabol
panel
screen
sampl
collect
subject
live
geograph
area
tbd
subject
part
irbapprov
protocol
iii
control
sampl
set
control
sampl
set
region
lyme
diseas
endem
consist
sampl
collect
patient
resid
near
reno
nv
sampl
submit
copp
laboratori
human
herpesviru
test
deidentifi
includ
studi
test
method
tbec
eia
method
sampl
screen
presenc
igg
igm
antibodi
tbec
use
antitbev
elisa
igg
euroimmun
catalog
antitbev
elisa
igm
euroimmun
catalog
per
manufactur
recommend
assay
protocol
assay
employ
inactiv
tbev
antigen
strain
optic
densiti
od
ratio
valu
calcul
sampl
refer
calibr
provid
test
kit
sampl
od
ratio
exceed
baselin
valu
reflex
confirmatori
powv
ifa
ii
ifa
method
inhous
strain
powassan
viru
lineag
ii
sequenceconfirm
deer
tick
viru
dtv
isol
scapulari
tick
pool
along
viral
refer
strain
powassan
lb
dtv
world
refer
center
emerg
virus
arbovirus
galveston
tx
cultur
vero
cell
use
prepar
ifa
substrat
slide
three
differ
cultur
techniqu
test
determin
best
slide
manufactur
condit
vero
cell
infect
powv
grown
eightwel
chamber
slide
use
optim
cultur
condit
slide
fix
neutral
buffer
formalin
nbf
follow
cold
methanol
store
use
prior
test
substrat
slide
warm
min
humid
chamber
room
temperatur
block
normal
goat
serum
vector
laboratori
burlingam
ca
addit
min
patient
serum
andor
plasma
sampl
posit
neg
control
dilut
normal
goat
serum
igg
analysi
eurosorb
euroimmun
us
antihuman
igg
antibodi
buffer
igm
analysi
ad
slide
well
incub
min
h
incub
slide
wash
time
phosphatebuff
salin
pb
l
dylight
antihuman
igg
vector
laboratori
dilut
l
fluorescein
antihuman
igm
muspecif
secondari
antibodi
vector
laboratori
dilut
ad
well
slide
incub
min
wash
three
time
pb
slide
counterstain
evan
blue
rins
distil
water
mount
use
vectashield
mount
medium
vector
laboratori
examin
use
epifluoresc
microscop
positiveand
negativecontrol
sampl
includ
ifa
run
iii
optim
ifa
titrat
fluorochromeconjug
antihuman
secondari
antibodi
perform
determin
optim
concentr
assay
sampl
titrat
experi
perform
determin
optim
screen
dilut
ifa
yield
accept
sensit
minim
crossreact
heterologousflaviviru
hf
sampl
set
lowprnt
titer
sampl
analyz
duplic
assay
optim
screen
dilut
determin
lower
limit
detect
lod
ifa
reproduc
assess
test
sampl
posit
sampl
neg
sampl
duplic
assay
iv
wnv
method
sampl
test
presenc
igg
igm
antibodi
wnv
qualit
eia
euroimmun
us
result
analyz
per
manufactur
recommend
protocol
v
clinic
test
tbd
sampl
test
tbec
eia
sampl
tbec
od
ratio
baselin
test
optim
powv
ifa
wnv
eia
powv
ifaposit
sampl
submit
nysdoh
prnt
prnt
rather
prnt
use
ensur
specif
though
expect
sensit
lower
nontbd
sampl
test
tbec
wnv
eia
sampl
higherthanbaselin
tbec
od
ratio
test
optim
powv
ifa
two
marshfield
clinic
sampl
powv
ifa
posit
also
test
prnt
control
sampl
test
tbec
eia
sampl
abovebaselin
od
ratio
reflex
confirmatori
ifa
vi
statist
analysi
analyt
sensit
calcul
true
posit
true
posit
fals
neg
analyt
sensit
determin
use
arboviru
enceph
panel
analyt
specif
calcul
true
neg
true
neg
fals
posit
limit
detect
calcul
lowest
prnt
titer
detect
powv
igg
assay
analyt
specif
determin
use
hf
sampl
set
seropreval
calcul
tbd
nontbd
control
sampl
set
due
inabl
prnt
use
confirm
powv
igm
lack
crossreact
seen
hf
sampl
sampl
powv
igm
ifa
posit
powv
igg
posit
confirm
prnt
presum
true
posit
sampl
neg
powv
igm
ifa
powv
igg
consid
fals
posit
wnv
igg
eia
posit
prnt
neg
